Table 3.
Outcomes of Experimental (combination or oral FU) Versus Control Arm (IV FU) by Treatment and Age
| Treatment Arm | DFS** |
OS* |
TTR* |
Deaths Within 6 Months, Experimental Versus Control |
||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | HR | 95% CI | % | P | |
| All trials | ||||||||
| Age < 70 years (n = 11,953) | 0.85 | 0.80 to 0.90 | 0.87 | 0.81 to 0.93 | 0.84 | 0.79 to 0.89 | 0.91 v 0.80 | .5 |
| Age ≥ 70 years (n = 2,575) | 1.05 | 0.94 to 1.19 | 1.08 | 0.95 to 1.23 | 1.06 | 0.93 to 1.22 | 3.10 v 2.52 | .4 |
| P interaction | .001 | .004 | .002 | |||||
| Oxaliplatin based | ||||||||
| Age < 70 years (n = 5,420) | 0.78 | 0.71 to 0.86 | 0.83 | 0.74 to 0.92 | 0.77 | 0.69 to 0.85 | 0.88 v 0.82 | .8 |
| Age ≥ 70 years (n = 1,119) | 0.94 | 0.78 to 1.13 | 1.04 | 0.85 to 1.27 | 0.86 | 0.69 to 1.06 | 3.15 v 2.25 | .4 |
| P interaction | .09 | .05 | .36 | |||||
| Irinotecan based | ||||||||
| Age < 70 years (n = 3,750) | 0.89 | 0.80 to 0.99 | 0.90 | 0.80 to 1.03 | 0.88 | 0.79 to 0.98 | 0.90 v 0.43 | .1 |
| Age ≥ 70 years (n = 699) | 1.19 | 0.95 to 1.49 | 1.11 | 0.87 to 1.42 | 1.35 | 1.04 to 1.76 | 3.96 v 2.43 | .3 |
| P interaction | .02 | .13 | .002 | |||||
| Oral fluoropyrimidine | ||||||||
| Age < 70 years (n = 2,783) | 0.91 | 0.80 to 1.02 | 0.90 | 0.79 to 1.03 | 0.90 | 0.80 to 1.02 | 0.98 v 1.25 | .5 |
| Age ≥ 70 years (n = 757) | 1.14 | 0.92 to 1.41 | 1.13 | 0.90 to 1.41 | 1.20 | 0.93 to 1.54 | 2.24 v 3.00 | .5 |
| P interaction | .13 | .16 | .09 | |||||
Abbreviations: DFS, disease-free survival; FU, fluorouracil; HR, hazard ratio; IV, intravenous; OS, overall survival; TTR, Time to recurrence.
*
Values < 1 favor experimental arm.